Cyclacel Pharma (CYCC) Reports Q1 Loss Per Share of $0.19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results
May 12, 2015 4:05 PM EDT-- Approximately 20% of prespecified events remaining in SEAMLESS before study unblinding -- -- Received FDA clearance for the first-in-human Phase 1 study of CYC065 CDK inhibitor -- -- Conference Call Scheduled May 12, 2015 at 4:30 p.m. Eastern Time --
BERKELEY HEIGHTS, N.J., May 12, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of... More
